Form 4: Quest Diagnostics Director Sells 1,250 Shares

Quest Diagnostics Director Vicky B. Gregg reported the sale of 1,250 shares of common stock at $191.76 per share under a pre-planned trading arrangement.

Summary

• Vicky B. Gregg, a Director of Quest Diagnostics Inc. (DGX), reported a transaction involving the company's common stock.
• On November 25, 2025, Gregg disposed of 1,250 shares of common stock.
• The shares were sold at a price of $191.76 per share.
• Following this transaction, Gregg beneficially owns 17,037 shares of Quest Diagnostics common stock.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The sentiment is neutral. While a director selling shares can sometimes be viewed negatively, the transaction was pre-planned under a Rule 10b5-1 plan, mitigating concerns that it's based on new, adverse information. The number of shares sold is also not a significant portion of the director's total holdings.

Positives

• The transaction was executed under a Rule 10b5-1 plan, indicating it was pre-scheduled and not based on new, non-public information, which can reduce concerns about insider selling.

Negatives

• A director's sale of shares, even if pre-planned, reduces insider ownership and can sometimes be perceived as a slight negative by the market, although the number of shares sold is relatively small compared to the remaining beneficial ownership.

Future Outlook

NA

Industry Context

This is an insider transaction report and does not provide broader industry context or trends. It reflects a personal financial decision by a director within the diagnostic services industry.

Stakeholder Impact

• Shareholders: May observe a slight reduction in insider ownership, but the pre-planned nature of the sale under Rule 10b5-1 suggests it's a personal financial decision rather than a signal about the company's future performance.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-planned sale of a relatively small number of shares by a director. It does not provide new fundamental information about Quest Diagnostics' operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction is a personal financial decision by the insider, not an indicator of company-specific news.

Keywords

Quest Diagnostics, DGX, Insider Trading, Form 4, Stock Sale, Director Transaction, Rule 10b5-1